Sign in
Taking people in United KingdomPhase 1

CryptiVax-1001 Cancer Vaccine After Surgery and Chemotherapy for High-Grade Serous Ovarian Cancer

Tests the safety of CryptiVax-1001, a cancer vaccine, in adults with ovarian cancer.

Key facts

Who runs it
Epitopea Ltd
Where
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, and Sutton, United KingdomSee the 10 sites
Trial code
Registry title
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status
Recruiting
Phase
Phase 1
People taking part
50 people, planned
Started
5 Nov 2026
Expected to end
Apr 2029
Type of study
Interventional, 6 groups
Treatments tested
  • CryptiVax-1001
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with advanced high-grade serous ovarian, fallopian tube or primary peritoneal cancer. They must have finished surgery and first-line platinum chemotherapy, with no sign of the cancer growing.

Age
18 years or older
Sex
Women only
Disease stage
FIGO stage III or IV at first diagnosis; high-grade serous or mostly serous type; residual disease after surgery of 1 cm (0.4 in) or less; complete or partial response to chemotherapy, or no new lesion or clear progression if no measurable lesion
Earlier treatment
Must have had surgery (primary or interval debulking) and at least 4 cycles of first-line platinum-based chemotherapy (carboplatin and paclitaxel, or equivalent). The last dose must be 4 to 12 weeks before screening. Must not have had bevacizumab or a PARP inhibitor as first-line maintenance, or any cancer vaccine, checkpoint inhibitor or cell therapy.
Biomarker or test result
Known BRCA wild-type status, confirmed HRP, and an HLA type that is compatible with CryptiVax-1001

Main reasons for not taking part

  • Non-epithelial or low malignant potential ovarian tumours
  • Uncontrolled fluid in the belly or chest needing drainage within 4 weeks of screening
  • Another cancer within the past 3 years, with few exceptions
  • Active autoimmune disease needing immune-suppressing treatment
  • Past severe allergic reaction to mRNA-LNP therapies

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Able to comprehend and are willing to sign the ICF and willing to follow the study procedures
  • Female, aged 18 years of age or older at the time of informed consent
  • Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma of high-grade serous histology or other high-grade predominantly serous subtypes
  • The FIGO 2014 stage III or IV disease at initial diagnosis
  • Underwent optimal PDS or IDS with residual disease ≤1 cm (R0 or R1 resection)
  • Completed first-line platinum-based chemotherapy (minimum 4 cycles of carboplatin and paclitaxel, or equivalent, received in either neoadjuvant or adjuvant, or both settings)
  • In the presence of measurable target lesion, achieved CR or PR per investigator assessment based on RECIST 1.1 after completion of chemotherapy. In the absence of measurable target lesion, no new lesion or overt progression per investigator assessment based on RECIST 1.1 after completion of chemotherapy
  • A minimum of 4 weeks from screening since the last dose of first-line platinum-based chemotherapy but not more than 12 weeks from screening since the last dose of first-line platinum-based chemotherapy
  • No evidence of radiologic or clinical progression between the end of chemotherapy and baseline screening
  • Known BRCAwt status
  • HRP confirmed
  • No prior, current, or planned treatment with bevacizumab or PARPi in the first-line maintenance setting
  • ECOG performance status of 0 or 1
  • Adequate haematologic and organ function
  • Negative pregnancy test for WOCBP
  • HLA type matching Cryptivax-1001

Who cannot take part

  • Previous treatment with any cancer vaccine, checkpoint inhibitor, or adoptive cellular immunotherapy
  • Administration of any vaccine within 30 days prior to first dosing
  • Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 90 days or 5 half-lives of that drug (if known) prior to first dosing, whichever is longer
  • Non-epithelial or low malignant potential ovarian tumours
  • Concurrent malignancy or history of another malignancy within the past 3 years except for malignancies with a negligible risk of metastasis or death
  • Active autoimmune disease requiring systemic immunosuppression
  • Uncontrolled intercurrent illness that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments
  • History of anaphylactic reaction to mRNA-LNP therapies
  • Presence of uncontrolled ascites or pleural effusion requiring drainage within 4 weeks of screening

Where in United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust - Addenbrookes HospitalCambridge, United KingdomContact: Head of Development OperationsTaking people
  • The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research CentreEdinburgh, United KingdomContact: Head of Development OperationsTaking people
  • Beatson West of Scotland Cancer CentreGlasgow, United KingdomContact: Head of Development OperationsTaking people
  • St James's University HospitalLeeds, United KingdomContact: Head of Development OperationsTaking people
  • University Hospitals of Leicester NHS Trust -Leicester Royal InfirmaryLeicester, United KingdomContact: Head of Development OperationsTaking people
  • Guy's and St Thomas' NHS Foundation Trust - Guy's HospitalLondon, United KingdomContact: Head of Development OperationsTaking people
  • Royal Marsden NHS Foundation Trust - Royal Marsden HospitalLondon, United KingdomContact: Head of Development OperationsTaking people
  • University College London Hospitals NHS Foundation Trust Cancer Clinical Trials UnitLondon, United KingdomContact: Head of Development OperationsTaking people
  • Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston HospitalPreston, United KingdomContact: Head of Development OperationsTaking people
  • Royal Marsden NHS Foundation Trust - Institute of Cancer ResearchSutton, United KingdomContact: Head of Development OperationsTaking people

About the trial

What the trial wants to find out

Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer.

Read full original descriptionShow less

The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine.

Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy.

The main purposes of this study are therefore to:

* assess how well the study vaccine is tolerated and identify any side effects. * analyse the study vaccine's capacity to activate your immune system

The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.

The 6 groups in the trial

  • Dose level 1Treatment being tested

    Treatment: CryptiVax-1001

  • Dose level 2Treatment being tested

    Treatment: CryptiVax-1001

  • Dose level 3Treatment being tested

    Treatment: CryptiVax-1001

  • Dose level 4Treatment being tested

    Treatment: CryptiVax-1001

  • Dose level 5Treatment being tested

    Treatment: CryptiVax-1001

  • Recommended DoseTreatment being tested

    Recommended phase 2 dose or another safe dose, based on Dose Escalation part

    Treatment: CryptiVax-1001

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase I/Ib, Multi-centre, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of CryptiVax-1001, a mRNA Lipid Nanoparticle Therapeutic Cancer Vaccine, in Participants With FIGO Stage III-IV High-Grade Serous or Predominantly Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Following Optimal Primary/Interval Debulking Surgery and First-Line Platinum-Based Chemotherapy (OVACT Study)
Plain-language title
CryptiVax-1001 Cancer Vaccine After Surgery and Chemotherapy for High-Grade Serous Ovarian CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
10 November 2026